Theragenics soars on private takeover offer
This article was originally published in Clinica
Executive Summary
Prostate cancer treatment specialist Theragenics’ share price has climbed 36% after it reported it has received a sweetened bid from private equity firm Juniper Investment. The offer of $2.25-2.30 per share, or $69.9-71.4 million in total, is an increase on the $2.05-2.10 per share that Juniper originally proposed on 10 May. Theragenics has agreed to negotiate exclusively with Juniper until 11 June.